Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.
Cille Norman visits Ochsner in Metairie once a month to participate in the hospital's ALS care program. As part of that program, Norman has recorded 316 custom phrases, such as "I love you," ...
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND ...
Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...
SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...
NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Woolsey Pharmaceuticals today announced the successful completion of an extension to its Series B Preferred financing round by existing investors. Woolsey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results